SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Daiichi Sankyo Company, Limited DSNKY OTC

Other OTC • Healthcare • Drug Manufacturers - General • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Daiichi Sankyo Company, Limited (DSNKY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $18.55. It has a SharesGrow Score of 94/100, indicating a strong investment profile with 7 out of 7 criteria passed.

Financials: revenue is $1.9T, +21.8%/yr average growth. Net income is $295.8B, growing at +64.7%/yr. Net profit margin is 15.7% (healthy). Gross margin is 78% (+11.8 pp trend).

Balance sheet: total debt is $101.3B against $1.6T equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 2.53 (strong liquidity). Debt-to-assets is 2.9%. Total assets: $3.5T.

Analyst outlook: 2 / 2 analysts rate DSNKY as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 88/100 (Pass), Future 100/100 (Pass), Income 70/100 (Pass).

DSNKY SharesGrow Score Overview

94/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 88/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DSNKY

DSNKY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

DSNKY: +21.8%/yr revenue is, +64.7%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

DSNKY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet DSNKY: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 2.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

DSNKY: Gross margin is 78% (+11.8 pp trend), $34B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 88/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate DSNKY as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

DSNKY: Net profit margin is 15.7%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range17.44-28.21

Volume9.35K

Avg Volume (30D)511.96K

Market Cap$34.34B

Beta (1Y)-0.17

Dividend Yield$0.2424

Share Statistics

EPS (TTM)155.96

Shares Outstanding$1.9B

IPO Date2008-12-12

Employees18,726

CEOHiroyuki Okuzawa

Financial Highlights & Ratios

Revenue (TTM)$1.89T

Gross Profit$1.47T

EBITDA$436.13B

Net Income$295.76B

Operating Income$331.93B

Total Cash$720.73B

Total Debt$101.33B

Net Debt$-538.51B

Total Assets$3.46T

Price / Earnings (P/E)0.1

Price / Sales (P/S)0.02

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINUS23381D1028

Price Chart

DSNKY

Daiichi Sankyo Company, Limited ↗ · Other OTC

Healthcare • Drug Manufacturers - General

17.44 52WK RANGE 28.21

People Also View

Johnson & Johnson

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Gilead Sciences, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message